CenterBook Partners LP Acquires Shares of 38,354 Lantheus Holdings, Inc. $LNTH

CenterBook Partners LP acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 38,354 shares of the medical equipment provider’s stock, valued at approximately $2,552,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. M&T Bank Corp purchased a new position in Lantheus during the fourth quarter valued at $370,950,000. Norges Bank purchased a new stake in Lantheus in the 4th quarter worth $76,197,000. Hotchkis & Wiley Capital Management LLC purchased a new stake in Lantheus in the 3rd quarter worth $11,443,000. Reinhart Partners LLC. boosted its holdings in shares of Lantheus by 15.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after purchasing an additional 214,820 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Lantheus by 73.4% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider’s stock valued at $23,001,000 after purchasing an additional 189,814 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on LNTH shares. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Mizuho lifted their price objective on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Finally, JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Trading Down 0.0%

Shares of LNTH stock opened at $99.98 on Wednesday. The company has a market cap of $6.51 billion, a PE ratio of 24.09 and a beta of -0.03. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $104.00. The stock’s 50 day simple moving average is $88.99 and its two-hundred day simple moving average is $75.77. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the company posted $1.53 EPS. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.